OncoSec Medical Featured on San Francisco’s KGO-TV Channel 7

News Segment Focuses on Use of ImmunoPulse to Treat Metastatic Melanoma

SAN DIEGO – July 19, 2013 – OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, was featured in a news segment airing July 17 on San Francisco’s ABC affiliate KGO-TV Channel 7.

The news segment details the potential of OncoSec’s ImmunoPulse DNA-based immunotherapy to treat metastatic melanoma, and profiles one California patient who has undergone the therapy.

During the segment, Dr. Adil Daud, principal investigator of OncoSec’s Phase II metastatic melanoma trial, remarks about ImmunoPulse: “You can have responses not just to the tumors you’ve injected…but even to tumors you haven’t touched, even to tumors in other parts of the body that you have [not] done anything to or injected. [W]e think that it’s an immune memory that forms.”

To view the KGO-TV news segment and read the accompanying article (“Doctors use electricity to boost cancer treatment”), please visit the following link here.